Fermer le menu
Logo Tours
  • Barin F & Simon F. Les outils du dépistage de l’infection par le VIH : concepts, progrès et limites. Virologie 2013, 17(3) : 171-181. disponible ici.
  • Barin F et coll. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV1 genotypes A to E: an approach for HIV1 serological subtyping. AIDS Res Hum Retroviruses 1996, 12: 1279-1289.
  • Barin F et coll. Development and validation of an immunoassay for identification of recent Human Immunodeficiency Virus type 1 infections and its use on dried serum spots. J clin Microbiol 2005, 43 : 4441-4447.
  • Barin F et coll. Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic. J med Virol 2006, 78 : S13-S18.
  • Brand D, Moreau A, Cazein F, Lot F, Pillonel J, Brunet S, Thierry D, Le Vu S, Plantier JC, Semaille C, Barin F. Characteristics of patients recently infected with HIV-1 non-B subtypes in France : a nested study within the mandatory notification of new HIV diagnoses. J clin Microbiol 2014, 52 : 4010-4016.
  • Brand D, Capsec J, Chaillon A, Cazein F, Le Vu S, Moreau A, Pillonel J, Brunet S, Thierry D, Guillon-Grammatico L, Lot F, Barin F. HIV surveillance combining an assay for identification of very recent infections and phylogenetic analyses on dried spots. AIDS 2017, 31 : 407-416
  • Plantier JC et coll. V3 serotyping of human immunodeficiency virus type 1 infection: correlation with genotyping, limitations and identification of signature sequences. JAIDS, 1999, 20: 432-441.
  • Simon et coll. Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses 2001, 17: 937-952.
  • Chaix ML et coll. Stable frequency of HIV-1 transmitted drug résistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009, 23 : 717-724.
  • Frange P, Meyer L, Deveau C, Tran L, Goujard C, Ghosn J, Girard PM, Morlat P, Rouzioux C, Chaix ML; for the French ANRS CO6 PRIMO Cohort Study Group. Recent HIV-1 Infection Contributes to the Viral Diffusion over the French Territory with a Recent Increasing Frequency. PLoS One, 2012, 7(2):e31695.
  • Chaix ML et coll. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis 2013, 56(6) : 880-887.
  • Frange P, Meyer L, Ghosn J, Deveau C, Goujard C, Duvivier C, Tubiana R, Rouzioux C, Chaix ML; for the ANRS CO6 PRIMO Cohort Study Group. Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection. Clin Microbiol Infect. 2013 May;19(5):E252-5.
  • Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies. J Antimicrob Chemother. 2015 Jul;70(7):2084-9.
  • Chaillon A, Essat A, Frange P, Smith DM, Delaugerre C, Barin F, Ghosn J, Pialoux G, Robineau O, Rouzioux C, Goujard C, Meyer L, Chaix ML; on behalf the ANRS PRIMO Cohort Study. Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies. Retrovirology. 2017 Feb 21;14(1):15. doi: 10.1186/s12977-017-0339-4.
  • Descamps D et coll. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006, 78 : 153-160.
  • Descamps D et coll. Increasing prevalence of transmitted drug resistance mutations and non-B subtypes circulating in antiretroviral naive chronically HIV-infected patients from 2001 to 2006/2007 in France. JAC 2010, 65: 2620-2627.
  • Cazein et coll. Prevalence and characteristics of individuals with undiagnosed HIV infection in France: evidence from a survey on hepatitis B and C seroprevalence. JAIDS 2012, 60: e116-118.
  • Chaillon et coll. Decreased specificity of an assay for recent infection (EIA-RI) in HIV-1 infected patients on HAART : implications for incidence estimates. Clin Vaccine Immunol 2012, 19: 1248-1253.
  • Le Vu S et coll. Performance of an immunoassay at detecting recent infection among reported HIV diagnoses. AIDS 2009, 23: 1773-1779.
  • Le Vu S et coll. Population-based HIV-1 incidence in France, 2003-2008 : a modelling analysis. Lancet Infect Dis 2010, 10: 682-687.
  • Semaille C et coll. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses : experience after 2 years in France. J infect Dis 2007, 196 : 377-383.
  • Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, de Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, Chiax ML, AC43 ANRS Resistance Group. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance but higher diversity, clustering and virulence? JAC 2020, 75: 183-193.

Données épidémiologiques :

  • Cazein F et coll. Découvertes de séropositivité VIH et sida – France, 2003-2013. BEH 2015, 9-10 (Consulter l’article).
  • Capsec J et coll. Caractéristiques des infections VIH très récentes et réseaux de transmission à partir des données de la déclaration obligatoire, France, 2012-2014. BEH 2016, 41-42 (Consulter l’article).